Drugs / Acetylcystein
Acetylcystein
English name N-acetylcysteine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01771978 | Jun 2002 → Feb 2008 | ischemic disease | University Hospital, Strasbourg, France | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00463749 Comparator | Dec 2006 → Feb 2008 | myocardial infarction | University of Leipzig | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acetylcystein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00463749 ↗ |
| Known as | N-ACC | “The aim of this study was to assess the effects of N-acetylcysteine (N-ACC) on contrast-induced nephropathy (CIN) defined by Cystatin C (Cys-C) serum levels and to evaluate the...” PMID 21710343 ↗ Jun 2011 |
| Known as | N-acetylcysteine | “The aim of this study was to assess the effects of N-acetylcysteine (N-ACC) on contrast-induced nephropathy (CIN) defined by Cystatin C (Cys-C) serum levels and to evaluate the...” PMID 21710343 ↗ Jun 2011 |
| Route | Intravenous | “CONCLUSIONS: High-dose intravenous N-acetylcysteine reduces oxidative stress.” PMID 20466200 ↗ May 2010 |